Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Covington
Baxter
McKesson
AstraZeneca
Cipla
US Army
Federal Trade Commission
Cerilliant

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEXAVAR

« Back to Dashboard

Clinical Trials for NEXAVAR

Trial ID Title Status Sponsor Phase Summary
NCT00064350 Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is suspended while the drug is administered but returns to baseline rates when the agent is withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized discontinuation design was adopted in the present trial, conducted in a population who were potentially sensitive to sorafenib. PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works compared to placebo in treating patients with refractory non-small cell lung cancer.
NCT00064350 Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer Completed Eastern Cooperative Oncology Group Phase 2 RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon, pancreatic, lung, and ovarian. This activity was cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is suspended while the drug is administered but returns to baseline rates when the agent is withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized discontinuation design was adopted in the present trial, conducted in a population who were potentially sensitive to sorafenib. PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works compared to placebo in treating patients with refractory non-small cell lung cancer.
NCT00079612 Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer Completed Onyx Pharmaceuticals Phase 2 The purpose of the study is to: - Find out if BAY 43-9006 prevents the growth of tumors - For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. - Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. - Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
NCT00079612 Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer Completed Bayer Phase 2 The purpose of the study is to: - Find out if BAY 43-9006 prevents the growth of tumors - For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. - Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. - Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
NCT00093613 Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma Completed National Cancer Institute (NCI) Phase 1 This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for NEXAVAR

Condition Name

Condition Name for NEXAVAR
Intervention Trials
Hepatocellular Carcinoma 36
Carcinoma, Renal Cell 18
Carcinoma, Hepatocellular 14
Liver Cancer 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for NEXAVAR
Intervention Trials
Carcinoma 111
Carcinoma, Hepatocellular 76
Carcinoma, Renal Cell 41
Liver Neoplasms 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for NEXAVAR

Trials by Country

Trials by Country for NEXAVAR
Location Trials
United States 937
Germany 49
Canada 48
Japan 31
Korea, Republic of 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for NEXAVAR
Location Trials
Texas 52
California 47
New York 42
Florida 39
Pennsylvania 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for NEXAVAR

Clinical Trial Phase

Clinical Trial Phase for NEXAVAR
Clinical Trial Phase Trials
Phase 4 5
Phase 3 17
Phase 2/Phase 3 3
[disabled in preview] 158
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for NEXAVAR
Clinical Trial Phase Trials
Completed 126
Recruiting 54
Active, not recruiting 38
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for NEXAVAR

Sponsor Name

Sponsor Name for NEXAVAR
Sponsor Trials
National Cancer Institute (NCI) 94
Bayer 85
M.D. Anderson Cancer Center 15
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for NEXAVAR
Sponsor Trials
Other 213
Industry 157
NIH 95
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
UBS
Dow
Baxter
McKesson
US Department of Justice
Chinese Patent Office
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.